Press Release August 12, 2020

Capital Markets Team Advises Underwriters of $158.8 Million Freeline Initial Public Offering

The Life Sciences IPOs + Capital Markets team advised the underwriters of Freeline Therapeutics Holdings plc’s (Nasdaq: FRLN) initial public offering in the United States of 8,823,529 American Depositary Shares representing 8,823,529 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of approximately $158.8 million. In addition, Freeline has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 ADSs at the initial public offering price, less underwriting discounts and commissions.

Freeline is  a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases.

The Goodwin team was led by Mitch Bloom, Edwin O’Connor, Stephanie Richards, Andrew Whitworth, and Kristen Armstrong, and included Duncan Greenhalgh, Megan Gustafson, Yingying CaiJulie Tibbets, Steven Tjoe, Kristina Jacobs, Roger Cohen, Bryna Shmerling, Nikhil Sethi, Dan Karelitz, Robert Young, Asta Evans, Ben Gossels, Andrew Harrow, Bryce McCullagh, Jacqueline Klosek, Sarah Bock, Andre Amorim, and Ettore Santucci, with invaluable assistance from Marishka DeToy and Kaitlin Carragher.

For more details, read the press release and articles in Endpoints, Xconomy, and Seeking Alpha.